McKesson Corporation (MCK) - 10-K Summary
Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2004
Business Overview: A Fortune 16 corporation providing supply, information, and care management products and services to the healthcare industry. Operations are conducted through three primary segments: Pharmaceutical Solutions (94% of revenue), Medical-Surgical Solutions (4%), and Information Solutions (2%). The company distributes pharmaceuticals, medical-surgical supplies, and provides healthcare IT software and services.
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 | Change |
|---|---|---|---|
| Total Revenues | $69.5 billion | $57.1 billion | +21.7% |
| Gross Profit | $3.25 billion | $3.10 billion | +4.7% |
| Gross Margin | 4.67% | 5.43% | -76 bps |
| Net Income | $646.5 million | $555.4 million | +16.4% |
| Diluted EPS | $2.19 | $1.88 | +16.5% |
| Operating Cash Flow | $563.4 million | $710.3 million | -20.7% |
| Total Debt | $1.48 billion | $1.51 billion | -1.5% |
| Working Capital | $3.55 billion | $3.28 billion | +8.2% |
| Debt to Capital Ratio | 22.3% | 25.0% | -2.7% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Pharmaceutical Solutions segment, which grew 23% due to market growth, new customers, and expanded business with existing customers. Sales to customers' warehouses increased significantly.
- Margin Compression: Gross margin declined 76 basis points to 4.67%. This was caused by a higher proportion of lower-margin pharmaceutical sales, competitive pricing pressure, a $27.9 million LIFO charge, and a $33 million deferral of gross profit in the Automation business.
- Operating Expenses: Increased 4% to $2.26 billion. However, as a percentage of revenue, expenses decreased 54 basis points due to productivity improvements and the leveraging of fixed costs. Notable items included a $66.4 million credit from the reversal of customer settlement reserves in the Information Solutions segment.
- Segment Performance:
- Pharmaceutical Solutions: Operating profit decreased to $932.7 million (from $987.9 million) due to margin declines and a $30 million bad debt provision for a customer bankruptcy.
- Information Solutions: Operating profit more than doubled to $190.4 million (from $94.4 million), driven by the reversal of customer settlement reserves and improved gross margins.
- Medical-Surgical Solutions: Operating profit increased to $91.6 million (from $65.4 million) due to gross profit improvements and expense reductions from distribution center consolidation.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Specific 2005 guidance is referenced in a Form 8-K dated April 29, 2004. The company reorganized its operating segments effective April 2004, creating a new "Provider Technologies" segment.
- Accounting Litigation: As of March 31, 2004, 91 lawsuits remain pending related to the 1999 restatement of financial statements involving the former HBOC subsidiary. A trial is scheduled for September 12, 2005. The company states it is not feasible to predict the outcome or estimate potential losses, which could be material. The SEC investigation into the company was terminated in 2002, though investigations into former officers continue.
- Contract Contingency (NHS): A $500 million, 10-year contract with the UK's National Health Services (NHS) has experienced delays and increased costs. As of March 31, 2004, $76 million in net assets were invested. Failure to reach an amended implementation plan could result in material losses or asset impairment.
- Other Litigation:
- Employment Judgment: A $18.5 million judgment ($3.5M compensatory + $15M punitive) was entered against the company in May 2004 regarding wrongful termination and harassment claims. The company plans to appeal.
- Product Liability: Ongoing litigation regarding latex gloves and asbestos exposure (indemnified by Univar).
- Customer Concentration: The ten largest customers accounted for approximately 50% of total consolidated revenues, with the largest customer (Rite Aid) representing 11%.
Investor Verification Checklist
- Legal Exposure: Verify the status of the 91 pending securities lawsuits and the potential financial impact of the September 2005 trial date.
- NHS Contract: Monitor the outcome of negotiations with the UK NHS regarding the $500 million contract and the potential impairment of the $76 million asset base.
- Margin Trends: Assess the sustainability of gross margins given the competitive pressure in pharmaceutical distribution and the shift toward lower-margin warehouse sales.
- Customer Concentration: Evaluate the risk associated with the top 10 customers representing 50% of revenue, specifically the impact of Rite Aid's performance.
- Segment Reorganization: Review the financial impact of the April 2004 reorganization into the new "Provider Technologies" segment in the first quarter of fiscal 2005.